The use of D-amino acids is no longer reserved for research and development. D-amino acids are now frequently incorporated in peptide pharmaceuticals. For example, Goserelin (Zoladex), which contains a D-Ser(t-Bu) in its sequence, has been a commercial success in the treatment of prostate cancer. Also, the use of D-amino acids in Bivalirudin and Icatibant has benefited the cardiovascular area. With CBL’s ability to produce high quality material in large quantities, significant cost savings can be offered on the purchase of D-amino acids to CBL customers.
Some of the benefits of the incorporation of D-amino acids in peptides include,
- D-amino acid containing peptides can form specific and high affinity interactions with natural protein targets (4)
- D-amino acids are resistant to proteases,which can dramatically alter biological half-life in a beneficial way. (1)
- Peptides containing D-amino acids can be exploited for eliciting a “unique immune response” as opposed to L-peptides. (2).
- D-amino acids have been used to produce the enantiomers of portions of natural sequences. (3)
D-amino acid building blocks as well as many other peptide reagents are readily available from the small to large scale at CBL. Please see below for a list of D-amino acids currently in stock at CBL. Other D-amino acids are available upon request.
Please contact us to request more information on CBL technologies, or to obtain product information.
- Wei GX, Bobek LA. Antimicrob Agents Chemother. 2005 Jun;49(6):2336-42.
- M Sela, and E Zisman FASEB J. 11: 449-456.
- Brad L. Pentelute, Zachary P. Gates, Jennifer L. Dashnau, Jane M. Vanderkooi,
Stephen B. H. Kent Journal of the American Chemical Society 2008 130 (30), 9702-9707
- M. Eckert, V. N. Malashkevich, L. H. Hong, P. A. Carr
and P. S. Kim, Cell (Cambridge, Mass.), 1999, 99, 103–115
|
